Loading...
XNASZURA
Market cap157mUSD
Jan 07, Last price  
2.41USD
1D
-3.60%
1Q
-39.45%
IPO
-66.71%
Name

Zura Bio Ltd

Chart & Performance

D1W1MN
XNAS:ZURA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-60m
L
8,416,7103,549,127-60,360,000
CFO
-15m
L+1,305.56%
-1,098,146-1,071,033-15,054,000

Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
URL
https://zurabio.com/
IPO date
Jul 16, 2021
Employees
Domiciled in
US
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2023‑122022‑122022‑032021‑12
Income
Revenues
Cost of revenue
43,999
26,364
Unusual Expense (Income)
NOPBT
(43,999)
(26,364)
NOPBT Margin
Operating Taxes
(203)
(570)
Tax Rate
NOPAT
(43,796)
(26,364)
Net income
(60,360)
-1,800.70%
3,549
-57.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
116,407
10,000
BB yield
Debt
Debt current
356
Long-term debt
12,500
Deferred revenue
Other long-term liabilities
990
(8,072)
12,500
Net debt
(99,806)
12,842
(144,119)
Cash flow
Cash from operating activities
(15,054)
(1,071)
CAPEX
(12,000)
Cash from investing activities
(8,000)
(12,000)
Cash from financing activities
121,293
356
FCF
(58,225)
(11,935)
(384)
Balance
Cash
99,806
14
4,720
Long term investments
139,399
Excess cash
99,806
14
144,119
Stockholders' equity
(83,269)
119,319
(134,699)
Invested Capital
163,810
(9,214)
139,380
ROIC
286.12%
ROCE
EV
Common stock shares outstanding
33,064
17,250
Price
Market cap
EV
EBITDA
(43,999)
(26,364)
EV/EBITDA
Interest
Interest/NOPBT